e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Treatment of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Outcomes with omalizumab in Indian patients with allergic (IgE-mediated) asthma: Results at 16 and 28 weeks
A. Mahashur, D. Talwar, R. Guleria, M. Kotnis (Mumbai, Noida, Delhi, India)
Source:
Annual Congress 2013 –Treatment of asthma
Session:
Treatment of asthma
Session type:
Thematic Poster Session
Number:
907
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Mahashur, D. Talwar, R. Guleria, M. Kotnis (Mumbai, Noida, Delhi, India). Outcomes with omalizumab in Indian patients with allergic (IgE-mediated) asthma: Results at 16 and 28 weeks. Eur Respir J 2013; 42: Suppl. 57, 907
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study
Source: International Congress 2016 – Asthma points to ponder
Year: 2016
Health related quality of life in asthmatic subjects after 3 months treatment with inhaled corticosteroids
Source: International Congress 2015 – Co-existing diseases and asthma
Year: 2015
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Bronchial thermoplasty in patients with very severe asthma: Safety and clinical outcomes
Source: International Congress 2016 – Airway stenting and ablation
Year: 2016
Fluticasone propionate/formoterol therapy for asthmatic patients: Results of a non-interventional study
Source: International Congress 2016 – Asthma management
Year: 2016
P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016
Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016
Asthma control, symptoms and exacerbations across treatment levels in patients with asthma
Source: Annual Congress 2013 –Management of respiratory diseases in primary care
Year: 2013
SQ HDM SLIT-tablet is effective in patients not well-controlled in GINA treatment steps 2-4
Source: International Congress 2016 – Asthma management
Year: 2016
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Source: International Congress 2016 – Asthma management
Year: 2016
Real life experience of omalizumab on selected children with severe allergic asthma
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016
Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015
Clinical outcomes in non-eosinophilic versus eosinophilic asthma after 12 months specialist management
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015
Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Total and free IgE in evolution of severe asthma after omalizumab treatment
Source: International Congress 2016 – Asthma management
Year: 2016
Quality of life and asthma control in elderly asthmatics: A seven year follow-up – Results from the PRAXIS study
Source: International Congress 2016 – Asthma management in primary care
Year: 2016
Patients with allergic and eosinophilic asthma in the German severe asthma registry
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015
Adherence to the treatment of patients with bronchial asthma
Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage?
Year: 2015
The control of asthma in real life: Baseline evaluation of a long-term study
Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept